UNDERSTANDING PATIENT CENTRICITY IN PHARMACEUTICAL LAUNCHES
Patient-centricity is a healthcare philosophy that prioritizes the needs of patients in every aspect of care. In the generic pharmaceutical space, this means designing products, packaging, and information systems that improve accessibility and usage for patients while maintaining affordability. Patient-centric launches focus on:
- Quality and Safety: Ensuring that generics meet the same standards of quality, safety, and efficacy as the originator medicines.
- Education and Communication: Providing clear and accessible information on proper medication use, especially to digitally literate and illiterate populations.
- Availability and Accessibility: Ensuring widespread availability of medicines in various forms (e.g., calendar packs, unit doses, tamper-resistant packaging) to accommodate different patient needs.
- Patient Empowerment: Engaging patients in the process by providing resources such as digital or printed information leaflets.
THE ROLE OF GENERICS IN GLOBAL HEALTHCARE
Generics are indispensable in global healthcare for their ability to provide affordable, high-quality alternatives to brand-name drugs. This affordability, coupled with widespread availability, has significantly reduced healthcare costs across various markets, enabling more patients to access vital medications while alleviating pressure on national healthcare budgets. The savings generated by generic medicines are profound, creating a ripple effect that benefits patients, healthcare systems, and governments alike.
Cost Savings in the United States
The U.S. serves as a prime example of the transformative financial impact of generics on healthcare. According to the 2023 U.S. Generic & Biosimilar Medicines Savings Report (1) by the Association for Accessible Medicines (AAM), generic drugs accounted for an astounding 85% of all prescriptions filled in the country, but only 25% of the total pharmaceutical expenditure. The report also highlights that:
$2.6 trillion saved over the past decade due to the use of generics and biosimilars.
In 2022 alone, generics saved the U.S. healthcare system approximately $373 billion, with an average saving of $7.25 per prescription filled with a generic alternative.
Generics treating chronic conditions like cardiovascular diseases, diabetes, and mental health disorders accounted for significant portions of these savings, offering affordable, long-term treatment options for millions of Americans.
These savings enable healthcare systems to allocate resources to newer, innovative treatments, and help patients who are uninsured or underinsured to afford their medications.
European Markets and Savings
In Europe, generics also represent a large portion of medicine consumption and play a crucial role in controlling healthcare costs. According to IQVIA generics make up around 50-70% of the volume of medicines dispensed across the EU, while only contributing to about 30% of overall pharmaceutical expenditure (2).
Germany, Europe’s largest healthcare market, saves approximately €11 billion annually due to the widespread adoption of generics. Germany’s system of referencing drug prices, combined with the extensive use of generics in treating conditions like hypertension, diabetes, and cancer, has contributed to these savings.
France similarly reaps substantial benefits, with €8 billion in annual savings attributed to generics. Government policies in France encourage the use of generics through aggressive price regulation and mandatory substitution practices at the pharmacy level.
Italy also benefits from generic medicines, generating over €3 billion in savings annually. Italy’s healthcare system utilizes generic medicines to combat rising costs, particularly in public hospital settings where treatment for long-term illnesses like heart disease and respiratory conditions is common.
Asia-Pacific Region: Growth and Savings
The Asia-Pacific region is home to some of the fastest-growing pharmaceutical markets, with countries like India and China leading in both the production and consumption of generic drugs. India, often referred to as the “pharmacy of the world,” is the largest producer of generic medicines globally and provides affordable drugs to low- and middle-income countries worldwide.
In India, the government’s Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) (3) initiative focuses on promoting affordable generics through special stores, offering medicines at 50-90% less than branded alternatives. In 2022, the program saved Indian citizens approximately ₹13,000 crore (around $1.75 billion USD).
China, the world’s second-largest pharmaceutical market, has also seen increased adoption of generics due to government policies aimed at reducing healthcare spending. The Volume-Based Procurement (VBP) (4) policy is designed to lower drug prices by increasing the use of generics in hospitals. This program saved ￥53 billion (about $8 billion USD) in its first year alone.
Global Implications: Facilitating Access to Treatment
Generics play a crucial role in providing equitable access to essential medicines, particularly in low- and middle-income countries where access to healthcare is often constrained by high costs. The World Health Organization (WHO) has long advocated for the use of generic medicines to improve global health outcomes. By offering lower-cost alternatives, generics ensure that patients suffering from diseases like HIV/AIDS, tuberculosis, and malaria can access life-saving treatment.
The extensive cost-saving impact of generics across global markets cannot be overstated. Globally from the United States, Europe to Asia and Africa, generics provide essential, affordable healthcare solutions, enabling governments and healthcare providers to stretch their budgets further while ensuring patients have access to the medicines they need. With global healthcare costs rising, the role of generics will only become more critical, continuing to provide financial relief for patients and healthcare systems alike.
CHALLENGES AND COMPLEXITIES IN LAUNCHING GENERICS
Launching generic pharmaceuticals is a high-stakes endeavour, as it operates in a technically complex, time-sensitive environment. Despite this, optimised access to generic medicines is crucial for patients who rely on these drugs to prevent disease progression.
Moreover, not all launches follow the prescribed process. The decisions involved often carry inherent risks, and experience in managing these risks is vital to the success of a launch. Some key considerations include:
AUSTRALIA’S APPROACH TO PATIENT-CENTRIC GENERICS
Australia has long been a leader in adopting patient-centric approaches to healthcare, particularly when it comes to the use of generic medicines. The country’s National Medicines Policy emphasizes the importance of quality use of medicines, timely access, and the viability of the pharmaceutical industry. Generics play a pivotal role in this framework, offering affordable alternatives that help ensure healthcare sustainability. However, what sets Australia apart is its proactive stance on integrating digital technologies to enhance patient access to information, particularly through the digitization of Consumer Medicine Information (CMI) (5).
The Role of Consumer Medicine Information (CMI)
CMI leaflets are vital for informing patients about the safe and effective use of medicines. Traditionally, these leaflets were included as paper inserts in medication packaging. However, by the early 2000s, Australia began moving toward a more digital approach to distributing this information.
- In 2001, under the National Medicines Policy, the Australian government introduced an initiative to digitize CMIs, providing every pharmacy in the country with the infrastructure necessary to print CMI leaflets on demand. Each pharmacy received a $3,000 readiness payment to purchase laser printers and digital systems to provide CMIs electronically. This initiative not only reduced the need for paper-based leaflets but also ensured that patients received up-to-date and accurate information with each prescription.
- Pharmacists were incentivized to participate in this digital transformation, receiving a $1,000 incentive for early registration and ongoing payments for every CMI provided at the rate of 10 cents per subsidized prescription. The digitization of CMIs meant that patients could access information that was more accurate, current, and tailored to their needs, improving both medication adherence and health outcomes.
Benefits of Digital Adoption in Australia
The move towards digitized CMIs in Australia brought about several key benefits that greatly enhanced the patient experience, particularly when it comes to generic medicines.
- Accurate and Up-to-Date Information: One of the most significant advantages of digitizing CMIs is the ability to provide patients with the most current information available. Printed CMIs, especially in the generic space, can quickly become outdated if there are changes to the formulation, dosage instructions, or safety information. By moving this information online, patients and healthcare providers can ensure they have the most recent data at their fingertips.
- Easy Access and Searchability: Digital CMIs allow patients to easily access information about their medications through online portals or directly at the pharmacy. This reduces the risk of losing important medication instructions and provides a more convenient way for patients to retrieve information when they need it. Moreover, structured and searchable databases make it easier for pharmacists and healthcare providers to find relevant information and communicate it effectively to patients.
- Packaging-Agnostic: Digital CMIs remove the dependency on physical packaging, which can be cumbersome, particularly for patients taking multiple medications. In Australia, this was particularly relevant in the generic pharmaceuticals market, where the same medication might be offered in various packaging forms. Digital CMIs ensure consistency of information, regardless of how the product is packaged.
- Supports Remote and Rural Communities: Australia’s vast geography, with many remote and rural communities, poses challenges for healthcare delivery. Digital CMIs helped bridge the gap by ensuring that patients, even in remote areas, could access reliable and timely information about their medicines, a crucial factor in improving health outcomes in underserved regions.
The Role of Pharmacists in Digital CMI Delivery
Pharmacists have been central to the success of Australia’s digital CMI initiative. Under the Fourth Community Pharmacy Agreement (6) introduced in 2005, pharmacists were required to provide CMIs at key moments of patient care:
- The first supply of a medication to ensure the patient understands how to use it safely.
- At regular intervals, such as every six months for long-term therapies, to reinforce correct usage.
- When changes occur in the dosage form or content of the CMI, ensuring patients are always aware of the latest information.
- For medications with significant contraindications or complex dosing instructions (e.g., teratogenic drugs), providing CMIs became an essential part of the dispensing process.
- Upon patient request, CMIs were readily available to ensure informed patient decision-making.
These practices reflect Australia’s commitment to ensuring that patients are empowered to take control of their health through access to reliable, understandable medication information. Digital CMIs helped reduce confusion and miscommunication, especially for generic medications, where packaging and branding differences could otherwise lead to patient uncertainty.
Challenges in Digital Adoption
While the benefits of digital CMIs were clear, there were some hurdles in ensuring widespread adoption:
- Digital Literacy: One of the major barriers to the success of digital health initiatives in Australia, including the digitization of CMIs, has been the varying levels of digital literacy among the population. While younger generations, often referred to as “digital natives,” are generally comfortable accessing information online, older patients or those unfamiliar with technology may struggle to navigate digital platforms. This has required ongoing education efforts by pharmacists and healthcare providers to ensure that all patients can access the information they need.
- Internet Accessibility in Remote Areas: Although digital CMIs improved access to information for rural and remote communities, Australia’s geography posed challenges in terms of reliable internet connectivity. Efforts to expand internet infrastructure have been critical in overcoming this barrier, ensuring that even the most isolated patients can benefit from digital healthcare solutions.
- Patient Trust and Privacy: With the rise of digital health solutions comes increased concern over patient privacy and data security. Ensuring that digital platforms for accessing CMIs are secure and trustworthy has been a priority for Australian regulators, who have implemented stringent data protection measures.
The Future of Digital Adoption in Australia’s Pharmaceutical Sector
Looking forward, Australia’s approach to digital health is likely to continue evolving, with the integration of emerging technologies like artificial intelligence (AI) and machine learning (ML). These technologies could further enhance the delivery of patient-centric care by improving the personalization of CMIs based on patient profiles, streamlining the prescription process, and predicting patient needs more accurately.
Additionally, the role of mobile apps in delivering CMIs is expected to grow. By integrating CMIs into existing digital health platforms that allow patients to track medications, monitor side effects, and communicate with healthcare providers, Australia can further enhance patient empowerment and engagement.
A Model for Patient-Centric Care
Australia has taken a significant step forward in its approach to patient-centric generics, particularly with the adoption of digital tools and policies designed to make medicines more affordable and accessible. The Pharmaceutical Benefits Scheme (PBS) has been a cornerstone in these efforts, helping Australians save substantial amounts on their medications. Recent reforms, such as the introduction of 60-day prescriptions, have been especially impactful.
In 2023 alone, Australians saved $250 million due to these reforms, which allow patients to receive double the medication for chronic conditions like cardiovascular disease and diabetes, reducing the need for frequent doctor visits and pharmacy trips. Additionally, the government expects that over the next four years, these changes will generate $1.6 billion in savings for patients. This is in line with Australia’s broader efforts to integrate digital technologies into healthcare, such as the digitization of Consumer Medicine Information (CMI), which ensures patients have up-to-date, accessible information about their medications.
By reducing the cost of generics and improving access to essential medicines through digital initiatives, Australia continues to set a strong example of how healthcare systems can adapt to meet the evolving needs of patients while also achieving significant cost savings. Australia’s approach to patient-centric generics, underpinned by the digitization of CMIs, demonstrates the powerful role that digital solutions can play in improving patient outcomes. By making accurate, timely information more accessible, the country has not only enhanced the quality use of medicines but also created a more efficient and effective healthcare system. As digital adoption continues to expand, Australia’s model could serve as a blueprint for other countries looking to integrate technology into their generic pharmaceutical launch strategies.
- LEVERAGING TECHNOLOGY FOR FUTURE LAUNCHES
Looking ahead, the integration of artificial intelligence (AI) and machine learning (ML) is expected to revolutionize the launch process for generic pharmaceuticals. These technologies can: - Improve Predictability: By analyzing data, AI and ML can help forecast demand, assess risks, and ensure efficient supply chain management.
Enhance Speed to Market: Automating aspects of the development and launch process can reduce time to market, ensuring that patients receive timely access to essential medicines. - Ultimately, embracing these technologies can streamline launches and help pharmaceutical companies manage the complexities of entering diverse markets.
CONCLUSION: A PATIENT-FIRST MINDSET
Launching generic pharmaceuticals with a patient-first mindset should focus on accessibility and patient education; by leveraging technology, pharmaceutical companies can ensure that their launches meet patient needs while maintaining regulatory compliance and profitability. Adoption of digitisation of patient leaflet is one example which could lead to real-time benefit for patients as well as healthcare professionals.
In the evolving landscape of healthcare, putting patients at the heart of generic pharmaceutical launches will continue to drive innovation and improve global health outcomes.
Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of the company.
References and notes
- AJMC AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1 September 18, 2024 S.Jeremias
- IQVIA Whitepaper “Beneath the Surface: Unravelling the True Value of Generic Medicines “ April 2024
- Quality Medicines Available at Affordable Prices for All
https://www.india.gov.in/spotlight/pradhan-mantri-bhartiya-janaushadhi-pariyojana#:~:text=Pradhan%20Mantri%20Bhartiya%20Janaushadhi%20Pariyojana%20%28PMBJP%29%20is%20a,in%20quality%20and%20efficacy%20as%20expensive%20branded%20drugs. - China to further develop centralized drug procurement https://english.www.gov.cn/policies/latestreleases/202101/28/content_WS6012b66ac6d0f72576944b3f.html
- Consumer Medicine Information (CMI) https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg/consumer-medicines-information-cmi
- Community Pharmacy Agreements (CPAs) – Program Data – Agreements 4 to 7 | Australian Government Department of Health and Aged Care
